Intrinsic value of Omnicell - OMCL

Previous Close

$44.00

  Intrinsic Value

premium content

  Rating & Target

premium content

  Value-price divergence*

premium content

Previous close

$44.00

 
Intrinsic value premium content
 
Up/down potential premium content
 
Rating premium content
 
Value-price divergence* premium content

Premium access subscription - $499/yr

please register and log in before paying

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of OMCL stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.6

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  42.89
  32.30
  29.57
  27.11
  24.90
  22.91
  21.12
  19.51
  18.06
  16.75
  15.58
  14.52
  13.57
  12.71
  11.94
  11.25
  10.62
  10.06
  9.55
  9.10
  8.69
  8.32
  7.99
  7.69
  7.42
  7.18
  6.96
  6.76
  6.59
  6.43
  6.29
Revenue, $m
  693
  917
  1,188
  1,510
  1,886
  2,318
  2,808
  3,356
  3,961
  4,625
  5,346
  6,122
  6,952
  7,836
  8,771
  9,758
  10,794
  11,880
  13,015
  14,199
  15,432
  16,716
  18,051
  19,439
  20,881
  22,380
  23,938
  25,557
  27,240
  28,992
  30,814
Variable operating expenses, $m
 
  814
  1,045
  1,319
  1,639
  2,007
  2,424
  2,891
  3,407
  3,972
  4,585
  5,214
  5,921
  6,674
  7,470
  8,310
  9,193
  10,118
  11,084
  12,093
  13,143
  14,237
  15,374
  16,556
  17,784
  19,061
  20,387
  21,766
  23,200
  24,691
  26,243
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  686
  814
  1,045
  1,319
  1,639
  2,007
  2,424
  2,891
  3,407
  3,972
  4,585
  5,214
  5,921
  6,674
  7,470
  8,310
  9,193
  10,118
  11,084
  12,093
  13,143
  14,237
  15,374
  16,556
  17,784
  19,061
  20,387
  21,766
  23,200
  24,691
  26,243
Operating income, $m
  6
  103
  143
  191
  247
  311
  384
  465
  555
  653
  760
  908
  1,031
  1,162
  1,301
  1,447
  1,601
  1,762
  1,930
  2,106
  2,289
  2,480
  2,678
  2,883
  3,097
  3,320
  3,551
  3,791
  4,041
  4,300
  4,571
EBITDA, $m
  64
  168
  218
  277
  346
  425
  514
  615
  726
  847
  979
  1,121
  1,274
  1,435
  1,607
  1,787
  1,977
  2,176
  2,384
  2,601
  2,827
  3,062
  3,307
  3,561
  3,825
  4,100
  4,385
  4,682
  4,990
  5,311
  5,645
Interest expense (income), $m
  5
  9
  14
  21
  29
  38
  49
  61
  75
  90
  107
  125
  144
  165
  187
  211
  235
  261
  288
  317
  346
  377
  409
  442
  477
  513
  551
  590
  630
  672
  716
Earnings before tax, $m
  -2
  95
  129
  170
  218
  273
  334
  403
  480
  563
  653
  783
  887
  997
  1,114
  1,237
  1,366
  1,501
  1,642
  1,790
  1,943
  2,103
  2,268
  2,441
  2,620
  2,806
  3,000
  3,201
  3,411
  3,628
  3,855
Tax expense, $m
  -3
  26
  35
  46
  59
  74
  90
  109
  130
  152
  176
  211
  239
  269
  301
  334
  369
  405
  443
  483
  525
  568
  612
  659
  707
  758
  810
  864
  921
  980
  1,041
Net income, $m
  1
  69
  94
  124
  159
  199
  244
  295
  350
  411
  477
  572
  647
  728
  813
  903
  997
  1,096
  1,199
  1,306
  1,418
  1,535
  1,656
  1,782
  1,913
  2,049
  2,190
  2,337
  2,490
  2,649
  2,814

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  54
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  935
  1,165
  1,509
  1,919
  2,397
  2,946
  3,568
  4,264
  5,034
  5,877
  6,792
  7,778
  8,834
  9,957
  11,145
  12,399
  13,715
  15,095
  16,537
  18,042
  19,609
  21,240
  22,937
  24,700
  26,533
  28,437
  30,417
  32,474
  34,613
  36,838
  39,154
Adjusted assets (=assets-cash), $m
  881
  1,165
  1,509
  1,919
  2,397
  2,946
  3,568
  4,264
  5,034
  5,877
  6,792
  7,778
  8,834
  9,957
  11,145
  12,399
  13,715
  15,095
  16,537
  18,042
  19,609
  21,240
  22,937
  24,700
  26,533
  28,437
  30,417
  32,474
  34,613
  36,838
  39,154
Revenue / Adjusted assets
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
  0.787
Average production assets, $m
  208
  224
  290
  368
  460
  566
  685
  819
  967
  1,129
  1,304
  1,494
  1,696
  1,912
  2,140
  2,381
  2,634
  2,899
  3,176
  3,464
  3,765
  4,079
  4,404
  4,743
  5,095
  5,461
  5,841
  6,236
  6,647
  7,074
  7,519
Working capital, $m
  134
  116
  151
  192
  240
  294
  357
  426
  503
  587
  679
  777
  883
  995
  1,114
  1,239
  1,371
  1,509
  1,653
  1,803
  1,960
  2,123
  2,293
  2,469
  2,652
  2,842
  3,040
  3,246
  3,460
  3,682
  3,913
Total debt, $m
  254
  406
  599
  829
  1,098
  1,406
  1,756
  2,147
  2,580
  3,054
  3,568
  4,122
  4,716
  5,347
  6,015
  6,719
  7,459
  8,234
  9,045
  9,890
  10,771
  11,688
  12,641
  13,633
  14,662
  15,733
  16,845
  18,001
  19,204
  20,454
  21,755
Total liabilities, $m
  504
  655
  848
  1,078
  1,347
  1,655
  2,005
  2,396
  2,829
  3,303
  3,817
  4,371
  4,965
  5,596
  6,264
  6,968
  7,708
  8,483
  9,294
  10,139
  11,020
  11,937
  12,890
  13,882
  14,911
  15,982
  17,094
  18,250
  19,453
  20,703
  22,004
Total equity, $m
  432
  510
  661
  840
  1,050
  1,290
  1,563
  1,868
  2,205
  2,574
  2,975
  3,407
  3,869
  4,361
  4,882
  5,431
  6,007
  6,612
  7,243
  7,902
  8,589
  9,303
  10,046
  10,819
  11,621
  12,456
  13,322
  14,224
  15,161
  16,135
  17,149
Total liabilities and equity, $m
  936
  1,165
  1,509
  1,918
  2,397
  2,945
  3,568
  4,264
  5,034
  5,877
  6,792
  7,778
  8,834
  9,957
  11,146
  12,399
  13,715
  15,095
  16,537
  18,041
  19,609
  21,240
  22,936
  24,701
  26,532
  28,438
  30,416
  32,474
  34,614
  36,838
  39,153
Debt-to-equity ratio
  0.588
  0.800
  0.910
  0.990
  1.050
  1.090
  1.120
  1.150
  1.170
  1.190
  1.200
  1.210
  1.220
  1.230
  1.230
  1.240
  1.240
  1.250
  1.250
  1.250
  1.250
  1.260
  1.260
  1.260
  1.260
  1.260
  1.260
  1.270
  1.270
  1.270
  1.270
Adjusted equity ratio
  0.429
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438
  0.438

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  1
  69
  94
  124
  159
  199
  244
  295
  350
  411
  477
  572
  647
  728
  813
  903
  997
  1,096
  1,199
  1,306
  1,418
  1,535
  1,656
  1,782
  1,913
  2,049
  2,190
  2,337
  2,490
  2,649
  2,814
Depreciation, amort., depletion, $m
  58
  65
  74
  85
  99
  114
  131
  150
  171
  194
  219
  213
  242
  273
  306
  340
  376
  414
  454
  495
  538
  583
  629
  678
  728
  780
  834
  891
  950
  1,011
  1,074
Funds from operations, $m
  28
  134
  169
  210
  258
  313
  375
  444
  521
  605
  696
  785
  890
  1,001
  1,119
  1,243
  1,373
  1,510
  1,653
  1,801
  1,956
  2,118
  2,285
  2,459
  2,641
  2,829
  3,024
  3,228
  3,439
  3,659
  3,888
Change in working capital, $m
  -20
  28
  34
  41
  48
  55
  62
  70
  77
  84
  91
  99
  105
  112
  119
  125
  132
  138
  144
  150
  157
  163
  170
  176
  183
  190
  198
  206
  214
  222
  231
Cash from operations, $m
  48
  126
  134
  169
  210
  258
  313
  375
  444
  521
  604
  687
  784
  889
  1,000
  1,118
  1,242
  1,372
  1,508
  1,651
  1,800
  1,954
  2,116
  2,283
  2,457
  2,638
  2,827
  3,022
  3,225
  3,437
  3,657
Maintenance CAPEX, $m
  0
  -24
  -32
  -41
  -53
  -66
  -81
  -98
  -117
  -138
  -161
  -186
  -213
  -242
  -273
  -306
  -340
  -376
  -414
  -454
  -495
  -538
  -583
  -629
  -678
  -728
  -780
  -834
  -891
  -950
  -1,011
New CAPEX, $m
  -29
  -55
  -66
  -79
  -92
  -105
  -119
  -134
  -148
  -162
  -176
  -189
  -203
  -216
  -228
  -241
  -253
  -265
  -277
  -289
  -301
  -313
  -326
  -339
  -352
  -366
  -380
  -395
  -411
  -427
  -445
Cash from investing activities, $m
  -341
  -79
  -98
  -120
  -145
  -171
  -200
  -232
  -265
  -300
  -337
  -375
  -416
  -458
  -501
  -547
  -593
  -641
  -691
  -743
  -796
  -851
  -909
  -968
  -1,030
  -1,094
  -1,160
  -1,229
  -1,302
  -1,377
  -1,456
Free cash flow, $m
  -293
  48
  36
  49
  65
  87
  112
  143
  179
  221
  267
  311
  368
  431
  499
  571
  649
  731
  817
  908
  1,004
  1,103
  1,207
  1,315
  1,428
  1,545
  1,666
  1,793
  1,924
  2,060
  2,201
Issuance/(repayment) of debt, $m
  250
  160
  194
  230
  269
  309
  350
  391
  433
  474
  514
  554
  593
  631
  668
  704
  740
  775
  810
  846
  881
  917
  953
  991
  1,030
  1,070
  1,112
  1,156
  1,202
  1,251
  1,301
Issuance/(repurchase) of shares, $m
  18
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  266
  160
  194
  230
  269
  309
  350
  391
  433
  474
  514
  554
  593
  631
  668
  704
  740
  775
  810
  846
  881
  917
  953
  991
  1,030
  1,070
  1,112
  1,156
  1,202
  1,251
  1,301
Total cash flow (excl. dividends), $m
  -28
  207
  230
  279
  334
  395
  462
  534
  612
  695
  782
  865
  961
  1,062
  1,167
  1,276
  1,389
  1,506
  1,628
  1,754
  1,885
  2,020
  2,161
  2,306
  2,458
  2,615
  2,779
  2,949
  3,126
  3,310
  3,503
Retained Cash Flow (-), $m
  -30
  -124
  -151
  -179
  -209
  -240
  -272
  -305
  -337
  -369
  -401
  -432
  -462
  -492
  -521
  -549
  -577
  -604
  -632
  -659
  -687
  -715
  -743
  -772
  -803
  -834
  -867
  -901
  -937
  -975
  -1,014
Prev. year cash balance distribution, $m
 
  46
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  129
  79
  100
  125
  155
  190
  230
  275
  325
  381
  433
  499
  570
  646
  727
  812
  902
  996
  1,095
  1,198
  1,306
  1,418
  1,534
  1,655
  1,781
  1,912
  2,048
  2,189
  2,336
  2,489
Discount rate, %
 
  5.60
  5.88
  6.17
  6.48
  6.81
  7.15
  7.50
  7.88
  8.27
  8.69
  9.12
  9.58
  10.06
  10.56
  11.09
  11.64
  12.22
  12.84
  13.48
  14.15
  14.86
  15.60
  16.38
  17.20
  18.06
  18.96
  19.91
  20.91
  21.95
  23.05
PV of cash for distribution, $m
 
  122
  70
  83
  97
  111
  125
  138
  150
  159
  166
  166
  167
  164
  158
  150
  139
  127
  113
  99
  85
  71
  58
  47
  37
  28
  21
  15
  11
  7
  5
Current shareholders' claim on cash, %
  100
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers OmniRx, a dispensing system that automates the management and dispensing of medications at the point of use; SinglePointe, a software product that controls medications; AnywhereRN, that remotely queue automated dispensing cabinets; Pandora Analytics, a reporting and data analytics tool; and Savvy Mobile System, which provides a platform for hospital information systems. The company also provides OmniLinkRx, a prescription routing system; WorkflowRx, an automated pharmacy storage, retrieval, and packaging system; Central Pharmacy and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; and Anesthesia Workstation that manages anesthesia supplies and medications. In addition, it offers Omnicell Supply Solution, which automates the management and dispensing of medical and surgical supplies; Omnicell Open Supply Solution for inventory management; Supply/Rx Combination Solution for managing supplies and medications; Omnicell Tissue Center that manages the chain of custody for bone and tissue specimens; OptiFlex SS, a module for the perioperative areas; OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas; and OptiFlex MS, a system for managing medical and surgical supplies. Further, Omnicell, Inc. offers Central Pharmacy, Point of Care, and IV Solutions; software; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

FINANCIAL RATIOS  of  Omnicell (OMCL)

Valuation Ratios
P/E Ratio 1611.7
Price to Sales 2.3
Price to Book 3.7
Price to Tangible Book
Price to Cash Flow 33.6
Price to Free Cash Flow 84.8
Growth Rates
Sales Growth Rate 42.9%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 45%
Cap. Spend. - 3 Yr. Gr. Rate 7.7%
Financial Strength
Quick Ratio 7
Current Ratio 0.1
LT Debt to Equity 56.9%
Total Debt to Equity 58.8%
Interest Coverage 1
Management Effectiveness
Return On Assets -0.2%
Ret/ On Assets - 3 Yr. Avg. 3.7%
Return On Total Capital 0.2%
Ret/ On T. Cap. - 3 Yr. Avg. 5.5%
Return On Equity 0.2%
Return On Equity - 3 Yr. Avg. 5.5%
Asset Turnover 0.9
Profitability Ratios
Gross Margin 45.3%
Gross Margin - 3 Yr. Avg. 49.8%
EBITDA Margin 8.8%
EBITDA Margin - 3 Yr. Avg. 13.1%
Operating Margin 1%
Oper. Margin - 3 Yr. Avg. 7.5%
Pre-Tax Margin -0.3%
Pre-Tax Margin - 3 Yr. Avg. 6.8%
Net Profit Margin 0.1%
Net Profit Margin - 3 Yr. Avg. 4.5%
Effective Tax Rate 150%
Eff/ Tax Rate - 3 Yr. Avg. 73.1%
Payout Ratio 0%

OMCL stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the OMCL stock intrinsic value calculation we used $693 million for the last fiscal year's total revenue generated by Omnicell. The default revenue input number comes from 2016 income statement of Omnicell. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our OMCL stock valuation model: a) initial revenue growth rate of 32.3% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 5.6%, whose default value for OMCL is calculated based on our internal credit rating of Omnicell, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Omnicell.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of OMCL stock the variable cost ratio is equal to 89.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for OMCL stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for Omnicell.

Corporate tax rate of 27% is the nominal tax rate for Omnicell. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the OMCL stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for OMCL are equal to 24.4%.

Life of production assets of 7 years is the average useful life of capital assets used in Omnicell operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for OMCL is equal to 12.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $432 million for Omnicell - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 36.601 million for Omnicell is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Omnicell at the current share price and the inputted number of shares is $1.6 billion.


Premium access subscription - $499/yr

please register and log in before paying
RELATED COMPANIES Price Int.Val. Rating
CERN Cerner 67.15 prem.  prem.
BDX Becton Dickins 194.91 prem.  prem.
SPAN Span-America M 29.99 prem.  prem.
SWK Stanley Black& 141.43 prem.  prem.
MCK McKesson 166.62 prem.  prem.

COMPANY NEWS

▶ ETFs with exposure to Omnicell, Inc. : June 27, 2017   [Jun-27-17 03:30PM  Capital Cube]
▶ Omnicell reports 1Q loss   [May-04-17 09:16AM  Associated Press]
▶ Omnicell Acquires InPharmics   [Apr-19-17 08:00AM  PR Newswire]
▶ Is Omnicell, Inc. (OMCL) a Good Stock to Buy?   [Dec-20-16 02:51PM  at Insider Monkey]
▶ [$$] Investing From the Ground Up   [Sep-03-16 12:01AM  at Barrons.com]
▶ Omnicell reports 2Q loss   [Jul-28-16 05:55PM  AP]
Stock chart of OMCL Financial statements of OMCL Annual reports of OMCL
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.